

(43) International Publication Date
9 June 2016 (09.06.2016)(10) International Publication Number
WO 2016/089766 A1

(51) International Patent Classification:

C07D 401/06 (2006.01) A61K 9/00 (2006.01)
A61P 25/00 (2006.01) A61K 31/454 (2006.01)

(21) International Application Number:

PCT/US2015/062985

(22) International Filing Date:

30 November 2015 (30.11.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/086,691 2 December 2014 (02.12.2014) US
62/248,071 29 October 2015 (29.10.2015) US

(71) Applicant: MINERVA NEUROSCIENCES, INC.
[US/US]; 1601 Trapelo Road, Suite 284, Waltham, Massachusetts 02451 (US).

(72) Inventors: LUTHRINGER, Remy; 1601 Trapelo Road, Suite 284, Waltham, Massachusetts 02451 (US). OK-UYAMA, Masahiro; Mitsubishi Tanabe Pharma Corporation, 3-2-10, Dosho-machi, Chuo-ku, Osaka 541-8505 (JP).

(74) Agents: ELRIFI, Ivor R. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOSITIONS COMPRISING 2-((1-(2-(4-FLUOROPHENYL)-2-OXOETHYL)PIPERIDIN-4-YL)METHYL)ISOINDOLIN-1-ONE FOR TREATING SCHIZOPHRENIA



(57) Abstract: The disclosure provides a novel polymorph of Compound (I); 2-((1-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one monohydrochloride dihydrate, i.e., Form (A) of Compound (I)·HO·2H₂O. Pharmaceutical compositions comprising Form (A) of Compound (I)·HO·2H₂O and related methods of treatment are also disclosed.